KalVista Pharmaceuticals(KALV) - 2025 Q3 - Quarterly Results

Financial Performance - KalVista Pharmaceuticals reported no revenue for the three months ended January 31, 2025, and January 31, 2024[7]. - The net loss for the three months ended January 31, 2025, was $44.3 million, compared to a net loss of$29.0 million for the same period in 2024[15]. Expenses - Research and development expenses decreased to $12.6 million for the three months ended January 31, 2025, from$22.5 million in the same period last year, primarily due to reduced clinical trial expenses[7]. - General and administrative expenses increased to $30.3 million for the three months ended January 31, 2025, compared to$10.6 million for the same period in the prior fiscal year, mainly due to pre-commercial planning activities[7]. Cash Position - The company had cash, cash equivalents, and marketable securities of approximately $253.2 million as of January 31, 2025, up from$210.4 million as of April 30, 2024[13]. Regulatory and Product Development - KalVista has submitted seven regulatory applications globally for sebetralstat, with the first regulatory approval expected in June 2025[3]. - Data from the KONFIDENT-S study indicated that patients on long-term prophylaxis averaged 1.7 HAE attacks per month, with symptom relief achieved in a median of 1.3 hours using sebetralstat[7]. Financing Activities - The company raised a total of $160 million in aggregate gross proceeds through synthetic royalty financing and equity offerings in November 2024[7]. Shareholder Information - The weighted average common shares outstanding increased to 52,638,888 for the three months ended January 31, 2025, compared to 34,723,379 for the same period in the prior year[15]. Investor Relations - KalVista plans to host a virtual investor day on March 25, 2025, to discuss the commercialization strategy for sebetralstat[7].